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Nociceptive sensitizers are regulated in damaged joint tissues, including the 
articular cartilage, when osteoarthritic mice display pain behaviour. 
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Objective: Pain is the most common symptom of osteoarthritis yet where it 
originates in the joint and how it is driven is unknown.  
 
Methods: 10 week old mice underwent sham surgery or surgical joint 
destabilization by either partial meniscectomy (PMNX) or by destabilizing the 
medial meniscus (DMM). Pain-related behavior, by a variety of methods (von 
Frey, cold plate sensitivity, analgesimeter, incapacitance testing, forced flexion) 
was assessed weekly.  Once pain-related behavior was established, RNA was 
extracted from either whole joints or micro-dissected tissues (articular cartilage, 
meniscus, bone). RT-PCR was carried out for 54 genes known to regulate pain 
sensitization. Cartilage injury assays were performed using avulsed immature 
murine hips from wild type or genetically modified animals, or by explanting 
articular cartilage from porcine joints pre-injected with pharmacological 
inhibitors. NGF protein was measured by ELISA. 
 
Results: Mice developed pain-related behavior 8 weeks following PMNX or 12 
weeks following DMM. Nerve growth factor, bradykinin receptors B1 and B2, 
tachykinin and its receptor, were significantly regulated in the joints of mice 
displaying pain-related behavior. There was little regulation of inflammatory 
cytokines, leukocyte activation markers or chemokines. When tissues were 
analysed separately, NGF was consistently regulated in the articular cartilage. 
The other pain sensitizers were also largely regulated in the articular cartilage 
although there were some differences between the two models.  Nerve growth 
factor and tachykinin were strongly regulated by simple mechanical injury of 
cartilage in vitro in a TAK1, FGF2 and Src kinase dependent manner. 
 
Conclusion: Damaged joint tissues produce pro-algesic molecules including NGF 
in murine OA. 
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Pain is the most common presenting symptom of osteoarthritis (OA) and yet 
when and where pain arises from in the arthritic joint is not clear. The disease is 
characterized by significant changes in several joint tissues including the 
articular cartilage where degradation of the tissue is seen; the bone where 
remodeling occurs resulting in subchondral bone sclerosis, osteophyte formation 
and bony epiphyseal expansion; the synovium which is subject to thickening and 
episodic inflammation; and the joint capsule and ligaments which may become 
thickened and fibrotic (1). With the exception of the articular cartilage, joint 
tissues are highly innervated. During disease the cartilage itself can become 
aberrantly innervated (2). 
 
Joint replacement surgery is successful at alleviating pain in the majority of 
individuals with end-stage OA indicating that peripheral drivers of pain are 
critical for symptomatic disease. Central processes, arising either from spinal or 
supraspinal pathways, play a large part in pain amplification in chronic disease 
leading to chronic pain syndromes. These are extremely challenging clinical 
management problems. In a small minority of patients chronic pain fails to abate 
despite joint replacement surgery (3).  
  
Epidemiological studies highlight the complexity of pain in OA. The correlation 
between pain and radiographic change (osteophyte score, joint space narrowing) 
is modest and it is not unusual to see patients with advanced radiographic 
disease without any joint symptoms. Conversely patients may present with knee 
pain with little or no radiographic evidence of OA, often leading to diagnostic 
uncertainty. The presence of synovitis in an OA joint is frequently associated 
with painful disease, although this is most frequently seen in a joint with 
advanced disease where pathology in other tissues is also apparent (4,5). There 
is some correlation between pain and cytokine levels in the joint but these do not 
appear to correlate with structural changes (6). The conclusions from the studies 
thus far have pointed at the likelihood that multiple tissues may give rise to 
symptoms, perhaps at different stages of disease, and that central processes are 
key to patient perceived severity and persistence of pain. Many of these 
responses are likely to be modifiable by patient specific factors such as genetics, 
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epigenetics, environment and mental state (e.g. presence of anxiety or 
depression). 
 
Murine models of disease potentially offer a simplified system in which to 
examine complex behavioral traits, as it is possible to control for genetic 
heterogeneity and environment. Moreover, because the disease is induced in a 
single joint, there are not issues due to multiple joint involvement, and 
behavioral responses can be measured which rely on asymmetry. These are 
sensitive and quantitative. We have previously demonstrated that following joint 
destabilization induced by cutting the medial meniscotibial ligament (DMM), a 
well validated model of OA, mice display two distinct phases of pain-related 
behavior based on asymmetrical stance measured by incapacitance testing. The 
first phase occurs directly as a result of joint surgery; it is associated with 
significant synovitis in the joint and is present in the sham-operated as well as 
the destabilized joint. The mice then do not display pain behavior for a period of 
several weeks until the second phase of pain-related behavior at around 11 
weeks post surgery. This occurs only in the destabilized joints and not in the 
sham-operated controls (7). We have also demonstrated pain-related behavior 
following partial meniscectomy (PMNX), by measuring mechanical hyperalgesia, 
cold allodynia, mechanical allodynia and vocalizations in response to joint 
compression. Partial meniscectomy induces OA with more accelerated course 
compared with DMM. Using this model a similar, albeit more rapid, biphasic 
pain-related behavior response is seen (8). Taking a candidate gene approach we 
established that joints from mice exhibiting pain-related behavior post DMM, 
had raised levels of nerve growth factor (NGF) mRNA, and their pain was 
alleviated by neutralization of NGF using the soluble TrkA receptor (9). This 
places NGF as a key mediator of pain in murine OA, which accords well with 
human trials using anti-NGF as an analgesic strategy in OA patients (10) and 
enhanced hyperalgesia in osteoarthritic rats following intra-articular NGF 
injection (11).  
NGF is an inflammatory response gene typically induced by inflammatory 
cytokines. Mechanical injury to tissues of the joint is also able to induce 
inflammatory response genes in a cytokine independent way. Indeed mechanical 
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injury of cartilage rapidly activates several intracellular signaling pathways 
including the mitogen activated protein kinases (MAPKs) (ERK, p38 and JNK), 
Src kinases (12-14), TGF-activated kinase 1 (TAK1) (Ismail, unpublished data), 
NFkB (12,14),  and the Wnt pathway  (15,16). This type of injury response is also 
seen upon avulsion of the femoral cap of immature murine hip joints (17), and 
both lead to the induction of inflammatory response genes such as chemokines, 
proteases and interleukins. One mechanism by which chondrocytes sense injury 
is by rapid release of FGF2 from the pericellular matrix, leading to the induction 
of a number of down stream targets (13,18,19). Release of FGF2 probably 
accounts for much of the ERK MAPK activation upon cartilage injury, but does 
not account for the activation of inflammatory signaling (TAK1, JNK, p38) upon 
injury (14). 
 
In the work presented here, we identify pain-sensitizing molecules in addition to 
NGF that are regulated in the joint when the mice develop OA-related painful 
behavior, in which tissues these molecules are being regulated, and what 
controls their regulation. 
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Methods: 
 
Animals: Mice were kept in approved animal-care facilities and were housed 5 
per cage in standard individually ventilated cages, maintained with a 12 h/12h 
light/dark cycle at an ambient temperature of 21°C. Animals were fed a certified 
mouse diet (RM3 from Special Dietary Systems, Essex, UK) and water ad libitum. 
Animal experiments were performed following local ethical and statutory 
approval. Male (DMM) and female (PMNX) C57Bl/6J mice were obtained from 
Charles River, UK at either 4 weeks (for hip avulsion experiments), or 9 weeks 
(for surgical joint destabilization). Fgf2-/- Tnfrp75-/-, Tnfrp55-/-, Myd88-/-, Jnk2-/- 
mice were originally obtained from Jackson Laboratory, USA. Littermate or 
appropriately matched wild type mice were used as controls. Porcine trotters 
from male 6-9 month old pigs were obtained within 12 hours of slaughter from a 
local abattoir.  
 
Surgical joint destabilization was performed either by PMNX or by DMM as 
previously described (8,20). Sham- operated mice or the contralateral joints 
were used as controls. Behavioral assessments were performed weekly. 
Consistent pain-related behavior was judged as painful behavior when it was 
significantly deviated from the sham-operated control. Joints were taken either 
for RNA extraction or for histology, the latter being scored according to OARSI 
guidelines and expressed as a summed score where the 3 highest joint scores 
(from all four sections of the joint) are added together. For separation of joint 
tissues, the articular cartilage, menisci and epiphyses (after cartilage removal) 
were removed by micro-dissection under an operating microscope. These 
methodologies are described in detail in (21,22).  
 
Pain-related behavior assessments: Prior to surgery animals were 
acclimatized to the behavioral assessment. Measurements of pain-related 
behavior, as described previously (7,8), were taken at regular intervals post-
surgery either by Driscoll, (DMM) or by Knights/Gentry (PMNX) , with each 
assessor  being blinded to treatment. Briefly, mechanical allodynia was assessed 
using von Frey filaments to the ipsilateral hindpaw. Mechanical hyperalgesia was 
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determined using an analgesy-meter (7200, Ugo-Basile, Milan, Italy), where an 
increasing pressure stimulus is applied to the dorsal surface of the ipsilateral 
hind paw until the mouse withdraws. Cold allodynia was assessed using a cold 
plate (Ugo Basile, Milan, Italy) (100C). Paw withdrawal latency was recorded as 
amount of time (seconds) before mice withdrew.  These are measures of 
hypersensitivity/allodynia distal to the joint. Mechanical allodynia at the joint 
was measured by number of vocalisations to 10 forced flexions of the knee joint, 
and by Linton incapacitance testing. Where more than one assessment was 
performed in the same mouse, care was taken to ensure the order of assessment 
was the same to minimize risk of sensitization of subsequent tests: incapacitance 
testing, von Frey, paw pressure, cold plate, then forced knee flexion. A maximum 
of 3 tests were performed in one session with at least 10 minutes between each 
test. 
 
Murine hip cartilage injury: 5-6 week old animals (wild type or KO, male or 
female) were culled by cervical dislocation and the acetabulofemoral joint 
exposed by blunt dissection as described previously (17). Hips were either 
immediately snap frozen (0 time) or were cultured in serum-free medium for up 
to 24h before snap freezing for RNA extraction (6 hips per point).  
 
Porcine cartilage injury: Trotters were washed in Virkon and skin removed. 
For injection studies, 2ml of a pan receptor FGFR inhibitor (SB402451 100nM), 
MEK inhibitor (UO126, 5M), p38 MAPK inhibitor (SB202190, 5M), TAK1 
inhibitor (5Z-7-oxozeaenol, 1μm), Src inhibitor (PP2, 10 M) or vehicle was 
injected into the metacarpophalangeal joint as previously described (14). 
Articular cartilage approximately 0.5g was dissected into serum free medium 
containing further inhibitor or vehicle and cultured. Explants were snap frozen 
for RNA extraction, or medium was analysed for NGF protein by ELISA using a 
commercial kit according to manufacturer’s instructions (Promega, Madison, 
USA). 
 
RNA extraction and RT-PCR: RNA extraction from whole and micro-dissected 
joint tissues (21,22), from avulsed acetabulofemoral joints (17), or from porcine 
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metacarpophalangeal cartilage (14) was performed as described previously. 
Only RNA with RIN > 8 was analysed further. Murine RNA was analysed on two 
custom-made microfluidic cards (Thermo Scientific, UK) carrying hydrolysis 
probes, interrogating 54 known pain-regulating genes (Table 1 and 
Supplementary Table 1). Porcine derived cDNA was interrogated by individual 
hydrolysis probe assays (Thermo Scientific, UK) (Supplementary Table 2).  
 
Statistics 
All groups of data were checked for approximation to the Gaussian distribution 
using the D’Agostino and Pearson omnibus normality test. Distributions were 
considered to be Gaussian if the p value for the null hypothesis was greater than 
0.05. Where multiple comparisons between multiple endpoints were performed 
we used a Bonferoni post hoc test to adjust for multiplicity. The tests performed 
at each case are described in the text and in the figure legends. To derive the 
number of animals required and samples for PCR analyses, we performed power 
calculations based on previous data (8,21). Statistical tests were performed on 
Graphpad Prism, version 6, unless otherwise stated. 
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Results: 
 
Joint destabilisation causes pain-related behavior. We first confirmed the 
development of pain-related behavior following joint destabilization using two different 
models: PMNX and DMM. Figure 1 shows that pain assessment measurements 
differentiate sham-operated from PMNX (A, B, C and D) or DMM-operated (E, F and G) 
mice at 8 weeks and 12 weeks post-surgery respectively. Both of these are in 
accordance with previously published work (7,8). All pain assessments including 
mechanical allodynia, thermal and mechanical hyperalgesia showed a similar temporal 
trend even though some are measuring sensitivity at a site distal to the joint (von Frey, 
analgesymeter, cold plate) and some are measuring sensitivity at the joint itself 
(vocalisations, Linton incapacitance).  Time of onset and persistence of pain-related 
behavior after DMM (up to 20 weeks), was confirmed, by incapacitance testing, in a 
number of repeat studies (data not shown). Early post-operative pain was not 
measured in PMNX mice as the first behavioral assessment was performed at week 1 
(after post operative synovitis has largely settled). Histological analysis of joints was 
performed at the time of onset of painful behavior (8 weeks for PMNX, 12 weeks for 
DMM). The chondropathy score was similar for both models and showed significant 
cartilage loss; extending at least to the tidemark, and often to the subchondral bone. 
Formal scoring for synovitis was not performed as it was deemed unreliable from 
coronal sections, but no increased joint inflammation was observed in animals with 
pain related behavior. Gene expression profiling of the joint was performed later to look 
for inflammatory gene change within the joint. 
 
Regulation of pain-sensitizing molecules in the joints of mice with pain-related 
behavior. Next we designed microfluidic cards that included hydrolysis probe assays 
for 54 genes known to be involved in pain sensitization. These included a number of 
neuropeptides and neurotrophic factors e.g. NGF, neuropeptide Y, tachykinin (TAC1, 
also known as substance P), their receptors, as well as a number of inflammatory 
molecules e.g. chemokines, cytokines and leukocyte activation markers.  
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Of the 54 genes examined, expression was detected for only 39 in whole joint extracts of 
PMNX-operated mice (8 weeks post surgery) (Table 1). Of these, 10 were regulated in 
PMNX compared with sham-operated joints (Table 1). This list included NGF (expected 
from our previous study) as well as TAC1, TACR1, and the bradykinin receptors 
(BDKRB1 and 2). TRPV4 and VEGFA were significantly but weakly (<1.5 fold) up 
regulated. Interestingly, of all the inflammatory genes tested, only TNF was modestly 
regulated above sham levels (1.51 fold). There was no increase in IL1 nor any 
chemokine or leukocyte activation marker associated with general inflammation, nor 
specifically implicated in neuronal sensitization e.g. CCL2 (23). The full list of 54 genes, 
including the 15 genes whose expression products were not detected in the joint, can be 
found in Supplementary Table 1. 
 
Tissue localization of pain sensitizing molecules. We explored where in the joint 
these molecules were being regulated. The experiment was repeated, only this time, 
joint tissues were micro-dissected (articular cartilage, epiphysis and meniscus) and 
where necessary, pooled for RNA extraction according to our previously described 
protocol (21,22). The same 54 genes were examined by qRT-PCR, using microfluidic 
cards. Table 2 shows those genes that were differentially up-regulated in the separated 
joint tissues of PMNX mice displaying pain-related behavior.  The results show that of 
the 10 genes regulated in whole joints, 5 were regulated in micro-dissected tissue from 
joints of animals exhibiting pain-related behavior compared with sham-operated 
controls (no pain). Furthermore, gene regulation was largely in the articular cartilage 
rather than the bone or meniscus. These included NGF, TAC1, TAC1 receptor (TACR1) 
and BDKRB1. BDKRB1 was also regulated in the meniscus. BDKRB2 was regulated only 
in the tibial epiphysis. Genes that were regulated in the whole joint but not picked up in 
the cartilage, meniscus or bone included HAS1, NPY, TNF, TRPV4 and VEGF. It is 
possible that these molecules were regulated in the synovium; one tissue that we have 
not been able to examine separately in this type of analysis.   
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To determine the robustness of these observations we then repeated the experiment in 
the DMM OA model and analysed RNA from micro-dissected tissues from sham or 
DMM-operated joints at a time when mice had established pain-related behavior (20 
weeks post surgery) (Table 2). Of the 5 pain-sensitizers regulated in the joint tissues of 
PMNX mice, all were regulated in joint tissues from DMM compared with sham-
operated joints. BDKRB1, BDKRB2 and NGF were strongly and significantly up-
regulated in the articular cartilage from these joints. Unlike PMNX, all genes examined 
were regulated in the meniscus of DMM operated joints. Only TACR1 and BDKRB1 were 
regulated in the bone. 
 
Pain-sensitizing molecules are strongly regulated by cartilage injury in vitro. As 
most of the genes were regulated in the damaged articular cartilage in vivo, we asked 
whether cartilage injury per se was sufficient to induce their regulation. We utilized a 
previously described murine hip cartilage injury assay in which the cartilaginous 
femoral head is avulsed from the femur of 5 week old mice (17). Figure 2A-D shows the 
induction of BDKRB1, BDKRB2, TAC1 and NGF in response to avulsion injury. Apart 
from TACR1 (data not shown), all genes were robustly induced by cartilage injury, with 
regulation first evident at 2h post injury. Induction of NGF was particularly strong, 
peaking at 300 fold (compared with time 0 levels) at 8h post injury (Figure 2D). 
Increased NGF protein secretion, following explantation injury, was detected by ELISA 
(Figure 2E).  Cycloheximide was added to the control explants to inhibit new synthesis 
of NGF. The pathways driving BDKRB1, BDKRB2, TAC1 and NGF regulation upon injury 
were examined further. 
 
Induction of NGF and TAC1 upon cartilage injury is FGF2, TAK1 and Src kinase-
dependent. To explore the molecular basis for regulation of pain-sensitizers following 
cartilage injury, we used two models; avulsion of the murine hip joint from genetically 
modified animals (17) and explantation from an intact porcine metatarsophalangeal 
joint in which pharmacological inhibitors had been injected into the joint prior to injury 
(14). Using a combination of these approaches we were able to examine the 
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involvement of FGF2, TNF in view of its regulation in the joint at the time of pain) 
and several intracellular signaling pathways that are known to be activated in response 
to cartilage injury. Table 3 summarizes the data from murine cartilage injury and shows 
that regulation of NGF and TAC1 upon injury are significantly FGF2-dependent. BDKRB1 
and BDKRB2 induction upon injury was MyD88 (an adapter protein involved in IL1 and 
TLR signaling) rather than FGF2-dependent, with MyD88 being a negative regulator of 
gene expression. The TNF receptors, p75 and p55 did not influence gene regulation 
upon cartilage injury for any of the genes tested. Figure 3 summarizes the 
pharmacological inhibitor studies for porcine cartilage injury. Gene regulation upon 
porcine cartilage injury was generally less pronounced, and the BDKRBs were 
inconsistently regulated 4h after injury. NGF and TAC1 regulation was robust, and both 
demonstrated FGF2-, TAK1- and Src-dependence, but not ERK or p38 MAPK-
dependence.  
As NGF regulation was significantly FGF2-dependent we speculated that pain-related 
behavior might be delayed in FGF2 null mice following induction of OA. When 
incapacitance testing was performed in FGF2 null mice following DMM surgery, rather 
than delaying the onset of pain-related behavior, mice displayed pain-related behavior 
4 weeks earlier than wild type animals (around 7 weeks post surgery) (Supplementary 
Figure 1A). Similar chondropathy scores were observed at the time of onset of pain-
related behavior for both groups of mice (Supplementary Figure 1B). 
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Discussion. 
We have shown previously that surgical models of OA can be used successfully to 
investigate pain responses and mechanisms of pain in vivo (7,8).  Here we present data 
showing that a handful of pain-sensitizing molecules, including NGF, BDKRB1, BDKRB2, 
TAC1 and TACR1, are regulated within the joints of mice at the time they display pain-
related behavior in two models of OA induced by surgical joint destabilization. The 
relative importance of these molecules in driving pain-related behavior is unclear. 
Neutralizing experiments performed by us previously have highlighted a key role for 
NGF as an analgesic target in murine OA (9). Others have shown this is also true for 
bradykinin receptor targeting (24).  Targeting TAC1 has not, to our knowledge, been 
examined in OA models.  
 
When gene regulation was examined at the individual tissue level, several of the genes, 
including NGF, were regulated within the articular cartilage in vivo, a tissue that is 
generally not thought to be involved directly in pain sensitization. Some pain sensitizers 
were also regulated in bone, although this was not the case for NGF or TAC1. Although 
the same five genes were regulated in both models of OA, there were some differences 
in the tissue specificity of this regulation. Gene regulation in the meniscus was very 
different between the two models, most likely because most of the load-bearing 
meniscus had been removed following PMNX.  Subtle differences between the models 
might also be explained by the timing of tissue sampling (time of pain onset (8 weeks) 
for PMNX rather than established pain (20 weeks) for DMM), and by gender (female 
mice for PMNX rather than male mice for DMM).  
 
Even though the induction of nociceptive sensitizers is strongly linked to inflammation 
(25), there was little inflammatory response in the joint at the time the mice 
demonstrated pain-related behavior; with modest regulation of TNF (1.5 fold above 
sham-operated joints) but no regulation of IL1, IL6, leukocyte activation markers or 
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chemokines such as CCL2. These inflammatory response genes are strongly regulated 
immediately following destabilization surgery when synovitis is also present, but this 
does not persist beyond 2 weeks (21). We were also unable to detect inflammatory gene 
regulation in the dorsal root ganglia at the time of pain-related behavior (data not 
shown). Along with our previous data showing that anti-TNF does not alter pain related 
behavior in DMM-operated mice (9), these results suggest that synovitis is not the 
principal driver of pain related behavior in these animals. Nonetheless, we are unable to 
exclude a minor role for synovitis at the onset of pain related behavior in murine OA.  
 
The results presented here reveal that mechanical injury is sufficient to regulate pain-
sensitizing molecules in cartilage in vitro, and raise the possibility that mechanical 
injury may be a key driver of pain sensitization in disease. This accords well with the 
observation that the chondropathy score at onset of pain-related behavior is 
comparable irrespective of OA model. Using a number of well validated cartilage injury 
models in combination with genetically modified tissues and pharmacological inhibitors 
we unraveled some of the cellular pathways responsible for induction of pain 
sensitizers upon injury. The regulation of both NGF and TAC1 was in part dependent 
upon FGF2, TAK1 and Src kinase. Interestingly, when we studied pain-related behavior 
in FGF2 knockout mice with surgically induced OA, lack of FGF2 did not delay pain-
related behavior. In fact earlier onset of pain-related behavior was observed, most likely 
relating to the more rapid disease course in these mice (20). In this case, the degree of 
cartilage damage in knockout animals at the onset of pain related behavior was similar 
to that observed in wild type mice, demonstrating once again, that pain-related 
behavior relates to chondropathy score. Regulation of NGF and TAC1 were strongly 
TAK1 dependent suggesting that the TAK1 pathway may prove to be more clinically 
important. Regulation of the BDKRBs upon cartilage injury appeared to be quite 
distinct, being MyD88 (negatively regulated), but not FGF2 dependent. The 
interpretation of these results is somewhat limited by the fact that their regulation in 
porcine cartilage was weak thus making inhibitor studies difficult to interpret. 
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NGF regulation in chondrocytes, along with their receptors, has been documented by 
others (26,27) and has been described in human OA cartilage; both at protein and 
mRNA level (2,28-30). This is also the case for bradykinin receptors and the tachykinin 
pathway (24,31). The expression of high and low affinity receptors for neurotrophic 
factors such as NGF in chondrocytes raises the possibility that regulation of these 
molecules upon injury may have direct effects on the cartilage in addition to 
sensitization of nociceptive fibres. Diverse functional roles for NGF have been described 
in chondrocytes and other tissues (32-38) and a disease modifying effect of NGF in 
osteoarthritis has been suggested after accelerated disease developed in a small subset 
of patients treated with a neutralizing antibody to NGF (10,39-41).  
 
One unexplained conundrum arising from this study is why painful behavior becomes 
evident only after substantial cartilage damaged has occurred. If pain-sensitizing 
molecules are induced and secreted in response to injury then why does pain not occur 
at the time of earliest cartilage damage, 2-4 weeks post surgery? One possibility is that 
there is enhanced sensitivity to injury in the deeper levels of the cartilage.  The change 
in pain-related behavior at this stage may also be related to reduced distances that 
nociceptive sensitizers need to diffuse to reach innervated tissues such as the 
subchondral bone. Although not yet demonstrated, pathological innervation of the 
cartilage may be developing in the mouse at this stage as it does in late human disease 
and this could be a pre-requisite for pain development (2). 
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Gene Sham-operated 
mice 
(normalized) 
±SD 
PMNX-operated/ 
sham-operated mice 
±SD 
P value 
BDKRB1 1.03±0.28 2.57±1.09 ≤0.05 
BDKRB2 1.01±0.19 3.51±0.88 ≤0.01 
HAS1 1.01±0.17 4.34±2.12 ≤0.05 
NGF 1.02±0.15 1.59±0.30 ≤0.05 
NPY 1.02±0.23 2.16±0.65 ≤0.05 
TAC1 1.12±0.64 2.33±0.69 ≤0.05 
TACR1 1.05±0.36 2.69±0.81 ≤0.05 
TNF 1.00±0.06 1.51±0.17 ≤0.01 
TRPV4 1.02±0.25 1.39±0.13 ≤0.05 
VEGFA 1±0.02 1.27±0.13 ≤0.05 
CALCA 1.14±0.76 1.34±0.45 NS 
CCL2 1.04±0.32 1.35±0.74 NS 
CCL19 1.03±0.32 1.39±0.25 NS 
CCR2 1.02±0.24 0.96±0.22 NS 
CCR7 1.01±0.18 1.13±0.13 NS 
CD14 1.02±0.26 1.22±0.30 NS 
CD68 1.03±0.28 1.14±0.21 NS 
CNR1 1.02±0.27 0.91±0.22 NS 
CNR2 1.01±0.18 1.26±0.13 NS 
GAL 1.03±0.29 1.08±0.30 NS 
GDNF 1.00±0.14 1.38±0.48 NS 
IL1α 1.04±0.30 0.93±0.21 NS 
IL1b 1.03±0.34 2.40±2.70 NS 
IL1R1 1.01±0.24 2.79±2.38 NS 
IL10 1.06±0.44 1.37±0.21 NS 
IL15 1.01±0.24 1.21±0.14 NS 
IL2 1.13.74 1.25±0.89 NS 
IL4 1.03±0.27 1.31±0.21 NS 
IL6 1.03±0.28 1.07±0.45 NS 
IL6RA 1.01±0.16 1.23±0.15 NS 
NOS2 1.04±0.34 1.09±0.28 NS 
NRTN 1.09±0.57 1.69±0.39 NS 
NTF3 1.01±0.19 0.97±0.15 NS 
NTF5 1.08±0.53 0.84±0.28 NS 
PENK 1.05±0.38 1.09±0.15 NS 
PSPN 1.14±0.76 1.34±0.79 NS 
PTGS2 1.06±0.38 0.88±0.62 NS 
TRPA1 1.02±0.24 1.24±0.23 NS 
TRPV1 1.02±0.28 1.44±1.03 NS 
 
Table 1. Up-regulated pain sensitizing molecules in PMNX mice displaying pain-
related behavior (8 weeks post surgery) 
RT-PCR of pre-selected genes (for full gene list and accession numbers, see Supplementary 
Table 1). Fold changes were normalized to ribosomal protein 18s and expressed relative to 
sham-operated mice. Sham n=3, PMNX n=4-5. Statistical significance was determined using 
a two-tailed T test. NS = not significant. Highlighted genes indicate those significantly 
regulated. 
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  BDKRB1 BDKRB2 TAC1 TACR1 NGF 
 
PMNX/sham-
operated fold 
change ± SD 
Cartilage 
 
P value 
4.47±2.16 
 
≤0.05 
2.07±1.34 
 
NS 
5.43±2.68 
 
≤0.05 
6.89±1.91 
 
≤0.001 
4.91±2.95 
 
≤0.05 
 Meniscus 
P value 
2.79±0.72 
≤0.01 
0.95±0.39 
NS 
1.32±0.50 
NS 
0.99±0.31 
NS 
1.17±0.59 
NS 
 Tibial 
epiphysis 
P value 
2.5±2.06 
 
NS 
2.27±0.30 
 
≤0.01 
3.95±4.70 
 
NS 
4.24±3.27 
 
NS 
1.35±0.57 
 
NS 
DMM/sham-
operated fold 
change ± SD 
Cartilage 
P value 
142.59±70.02 
≤0.001 
332.89±150 
≤0.001 
 
0.93±0.38 
NS 
 
1.1±1.07 
NS 
 
5.94±3.75 
≤0.05 
 
 Meniscus 
P value 
4.17±1.14 
≤0.005 
1.82±0.345 
≤0.01 
3.33±0.7 
≤0.001 
4.11±1.54 
≤0.001 
 
2.34±0.69 
≤0.05 
 Tibial 
epiphysis 
P value 
2.94±0.95 
 
≤0.01 
3.11±2.04 
 
NS 
13.88±12.14 
 
NS 
2.86±1.49 
 
≤0.001 
1.38±0.95 
 
NS 
Table 2. Regulation of pain sensitizing molecules in micro-dissected tissues from PMNX and DMM-
operated joints 
RNA was extracted from the micro-dissected tissues of PMNX, DMM or sham-operated joints either at 8 
weeks post surgery (PMNX) or at 20 weeks post surgery (DMM). RT-PCR was performed using custom-
made Taqman microfluidic cards. Genes were normalized to 18S and expressed relative to sham levels. 
Highlighted genes indicate those regulated significantly over sham levels. Values are the mean ± SD (n=3 
for PMNX, n=6 for DMM). Statistical significance was determined using a two-tailed T test. 
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Table 3. Pathways driving pain-sensitizing molecules upon murine cartilage injury. Hip cartilage from wild 
type (WT) or genetically modified animals (p75
-/-
, p55
-/-
, MyD88
-/-
, Fgf2
-/-
) were avulsed into serum free 
medium for 4h. RNA was extracted from 6 hips (pooled) for each experimental point (n=3). Fold changes were 
normalized to ribosomal protein 18s and expressed relative to WT levels ± SEM. Statistical significance 
was determined using one-way ANOVA with a Bonferroni post hoc test. P values are shown with those 
reaching statistical significance highlighted. NS – non-significant
  BDKRB1 BDKRB2 TAC1 NGF 
Knockout 
strain 
Fold change 4h 
relative to 0h 
 
    
P75 WT (±SD) 4.94±7.28 7.15±10.65 4.47±1.50 56.38±96.24 
 KO (±SD) 8.76±6.89 7.17±5.65 3.57±1.86 69.61±38.88 
 KO/WT (p value) 1.77 (NS) 1.02 (NS) 0.79 (NS) 1.23 (NS) 
P55 WT (±SD) 24.43±13.01 18.99±9.98 28.22±31.42 336.8±235.2 
 KO (±SD) 17.69±13.67 16.36±18.44 11.51±9.55 223.4±276.4 
 KO/WT (p value) 0.72 (NS) 0.86 (NS) 0.41(NS) 0.66 (NS) 
MyD88 WT (±SD) 10.97±2.19 10.15±2.27 74.61±46.15 92.52±10.78 
 KO (±SD) 29.66±9 26.44±4.05 45.9±39.15 120.7±38.66 
 KO/WT (p value) 2.7 (≤0.05) 2.6 (≤0.005) 0.61 (NS) 1.31 (NS) 
FGF2 WT (±SD) 6.29±1.99 6.05±0.56 14.11±7.63 152.50±46.67 
(n=8) KO (±SD) 8.01±1.3 6.12±1.49 6.03±2.38 59.65±21.17 
 KO/WT (p value) 1.27 (NS) 0.98 (NS) 0.427(≤0.05) 0.39 (≤0.05) 
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Figure 1. Pain behavior post joint destabilisation 
10-week old mice underwent partial meniscectomy (PMNX)(A-D), destabilization of the 
medial meniscus (DMM)(E-G) or sham surgery. Mice were assessed weekly until 
consistent pain-related behavior was observed. The following measurements were 
made: mechanical allodynia using von Frey hairs (A, E); cold allodynia using a cold plate 
(100C) (B, F); vocalisations to 10 knee compressions (C); mechanical allodynia by 
incapacitance testing (G); mechanical hyperalgesia using an analgesymeter (D). Each 
point represents the mean value ± SEM, n≥10.  Statistical significance was determined 
using a two-way ANOVA with a Bonferroni post hoc test (comparing destabilized (blue) 
with sham-operated (green) joints)(* p≤0.05,**p≤0.01, ***p≤0.001, ****≤0.0001). 
Histological scores of destabilized and sham-operated joints at 8 weeks (PMNX) and 12 
weeks (DMM) post surgery (H). 
 
Figure 2. Induction of pain sensitizing molecules upon cartilage injury 
Murine hips (6 pooled per experimental point)(RT-PCR) or porcine cartilage explants 
(protein measurements) were explanted and either snap frozen, or cultured for up to 8h 
in serum free medium or cycloheximide (CYCLO). Gene expression changes were 
obtained by RT-PCR. Fold changes were normalized to ribosomal protein 18s and 
expressed relative to 0hrs. Bars represent mean fold change ± SEM, n=3-6 experimental 
points. Statistical significance was determined using a one-way ANOVA: (A) BDKRB1 
(p<0.001); (B) BDKRB2 (p<0.001); (C) TAC1 (p<0.0001); NGF (p<0.0001).  (E) Protein 
secretion from injured cartilage explants was measured by ELISA. 
 
Figure 3. Pathways driving regulation of NGF, TAC1, BDKRB1 and BDKRB2 upon 
porcine cartilage injury  
Porcine metacarpophalangeal joints were injected with inhibitor or vehicle 2 hours 
prior to cartilage explantation. Explants were either snap frozen (open bars) or cultured 
for 4 hours in serum free medium containing vehicle (solid bars) or inhibitor (hatched 
bars). Inhibitors included: a pan FGFR inhibitor (SB402451, 100nM), TAK1 inhibitor 
(5Z-7-oxozeaenol, 1μM), Src inhibitor (PP2, 10 M), MEK inhibitor (UO126, 5M), p38 
MAPK inhibitor (SB202190, 5M). RNA was extracted and gene fold changes obtained 
by RT-PCR. Fold changes were normalized to ribosomal protein 18s and expressed 
relative to 0hrs. Bars represent mean fold change ± SEM, n=3. Statistical significance 
was determined using one-way ANOVA with a Bonferroni post hoc test.  Up-regulation 
of NGF and TAC1 upon injury was statistically significant for all experiments. P values 
are shown where there was a significantly different injury response in the presence of 
inhibitor (* p≤0.05, **p≤0.01, ***p≤0.001, ****p≤0.0001). 
 
Supplementary Figure 1 
Incapacitance testing and disease scores in wild type and FGF2-/- mice post DMM. 
(A) 10 week old wild type or FGF2-/- mice underwent DMM or sham surgery (WT only). 
Incapacitance testing was checked 4 times in the first week then weekly thereafter. 
Percentage weight bearing indicates the proportion of weight borne through the 
operated compared with non-operated joint. Data are expressed as mean ± SD. N=10  
(B) Summed cartilage scores in WT and FGF2-/- animals at the time at which animals first 
developed pain-related behavior following DMM (WT 11 weeks, FGF2-/- 7 weeks). N=3-5 
animals per group. 
 
 
 
 
 
 
 24 
 
Figure 1. Pain behavior post joint destabilisation 
10-week old mice underwent partial meniscectomy (PMNX)(A-D), destabilization of the 
medial meniscus (DMM)(E-G) or sham surgery. Mice were assessed weekly until 
consistent pain-related behavior was observed. The following measurements were 
made: mechanical allodynia using von Frey hairs (A, E); cold allodynia using a cold plate 
(100C) (B, F); vocalisations to 10 knee compressions (C); mechanical allodynia by 
incapacitance testing (G); mechanical hyperalgesia using an analgesymeter (D). Each 
point represents the mean value ± SEM, n≥10.  Statistical significance was determined 
using a two-way ANOVA with a Bonferroni post hoc test (comparing destabilized (blue) 
with sham-operated (green) joints)(* p≤0.05,**p≤0.01, ***p≤0.001, ****≤0.0001). 
Histological scores of destabilized and sham-operated joints at 8 weeks (PMNX) and 12 
weeks (DMM) post surgery (H). 
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Figure 2. Induction of pain sensitizing molecules upon cartilage injury 
Murine hips (6 pooled per experimental point)(RT-PCR) or porcine cartilage explants 
(protein measurements) were explanted and either snap frozen, or cultured for up to 8h 
in serum free medium or cycloheximide (CYCLO). Gene expression changes were 
obtained by RT-PCR. Fold changes were normalized to ribosomal protein 18s and 
expressed relative to 0hrs. Bars represent mean fold change ± SEM, n=3-6 experimental 
points. Statistical significance was determined using a one-way ANOVA: (A) BDKRB1 
(p<0.001); (B) BDKRB2 (p<0.001); (C) TAC1 (p<0.0001); NGF (p<0.0001).  (E) Protein 
secretion from injured cartilage explants was measured by ELISA. 
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Figure 3. Pathways driving regulation of NGF, TAC1, BDKRB1 and BDKRB2 upon 
porcine cartilage injury  
Porcine metacarpophalangeal joints were injected with inhibitor or vehicle 2 hours 
prior to cartilage explantation. Explants were either snap frozen (open bars) or cultured 
for 4 hours in serum free medium containing vehicle (solid bars) or inhibitor (hatched 
bars). Inhibitors included: a pan FGFR inhibitor (SB402451, 100nM), TAK1 inhibitor 
(5Z-7-oxozeaenol, 1μM), Src inhibitor (PP2, 10 M), MEK inhibitor (UO126, 5M), p38 
MAPK inhibitor (SB202190, 5M). RNA was extracted and gene fold changes obtained 
by RT-PCR. Fold changes were normalized to ribosomal protein 18s and expressed 
relative to 0hrs. Bars represent mean fold change ± SEM, n=3. Statistical significance 
was determined using one-way ANOVA with a Bonferroni post hoc test.  Up-regulation 
of NGF and TAC1 upon injury was statistically significant for all experiments. P values 
are shown where there was a significantly different injury response in the presence of 
inhibitor (* p≤0.05, **p≤0.01, ***p≤0.001, ****p≤0.0001). 
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Supplementary Figure 1 
Incapacitance testing and disease scores in wild type and FGF2-/- mice post DMM. 
(A) 10 week old wild type or FGF2-/- mice underwent DMM or sham surgery (WT only). 
Incapacitance testing was checked 4 times in the first week then weekly thereafter. 
Percentage weight bearing indicates the proportion of weight borne through the 
operated compared with non-operated joint. Data are expressed as mean ± SD. N=10  
(B) Summed cartilage scores in WT and FGF2-/- animals at the time at which animals first 
developed pain-related behavior following DMM (WT 11 weeks, FGF2-/- 7 weeks). N=3-5 
animals per group. 
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Supplementary Table 1 List of Taqman® hydrolysis probe-primer assays 
used for qPCR in murine tissues. Genes were selected because of their 
actions as inflammatory mediators and modulators of pain (reviewed in (1)). 
 
Symbol Name 
MGI 
Gene/Marker ID Assay number 
Artn* artemin MGI:1333791 Mm03024167_s1 
Bdkrb1 bradykinin receptor, beta 1 MGI:88144 Mm00432059_s1 
Bdkrb2 bradykinin receptor, beta 2 MGI:102845 Mm00437788_s1 
Bdnf* brain derived neurotrophic factor MGI:88145 Mm01334047_m1 
Calca 
calcitonin/calcitonin-related 
polypeptide, alpha MGI:2151253 Mm00801463_g1 
Ccl19 chemokine (C-C motif) ligand 19 MGI:1346316 Mm00839967_g1 
Ccl2 chemokine (C-C motif) ligand 2 MGI:98259 Mm00441242_m1 
Ccr2 chemokine (C-C motif) receptor 2 MGI:106185 Mm01216173_m1 
Ccr7 chemokine (C-C motif) receptor 7 MGI:103011 Mm01301785_m1 
Cd14 CD14 antigen MGI:88318 Mm00438094_g1 
Cd68 CD68 antigen MGI:88342 Mm00839636_g1 
Cnr1 cannabinoid receptor 1 (brain) MGI:104615 Mm00432621_s1 
Cnr2 
cannabinoid receptor 2 
(macrophage) MGI:104650 Mm00438286_m1 
Crh* corticotropin releasing hormone MGI:88496 Mm01293920_s1 
Gal galanin MGI:95637 Mm00439056_m1 
Gdnf 
glial cell line derived neurotrophic 
factor MGI:107430 Mm00599849_m1 
Has1 Hyaluronan synthase 1 MGI:106590 Mm00468496_m1 
Il10 interleukin 10 MGI:96537 Mm00439616_m1 
Il13* interleukin 13 MGI:96541 Mm99999190_m1 
Il15 interleukin 15 MGI:103014 Mm00434210_m1 
Il17a* interleukin 17A MGI:107364 Mm00439619_m1 
Il1a interleukin 1 alpha MGI:96542 Mm00439620_m1 
Il1b interleukin 1 beta MGI:96543 Mm01336189_m1 
Il1r1 interleukin 1 receptor, type I MGI:96545 Mm00434237_m1 
Il21* interleukin 21 MGI:1890474 Mm00517640_m1 
Il24* interleukin 24 MGI:2135548 Mm00474102_m1 
Il2 interleukin 2 MGI:96548 Mm00434256_m1 
Il4 interleukin 4 MGI:96556 Mm00445260_m1 
Il6 interleukin 6 MGI:96559 Mm99999064_m1 
Il6ra interleukin 6 receptor, alpha MGI:105304 Mm00439653_m1 
Ngf nerve growth factor MGI:97321 Mm00443039_m1 
Nos2 nitric oxide synthase 2, inducible MGI:97361 Mm01309898_m1 
Npy neuropeptide Y MGI:97374 Mm00445771_m1 
Nrtn neurturin MGI:108417 Mm00435387_m1 
Ntf3 neurotrophin 3 MGI:97380 Mm00435413_s1 
Ntf5 neurotrophin 5 MGI:97381 Mm01701591_m1 
Ntrk1* 
neurotrophic tyrosine kinase, 
receptor, type 1 MGI:97383 Mm01219407_m1 
Pdyn* prodynorphin MGI:97535 Mm00457573_m1 
Penk preproenkephalin MGI:104629 Mm01212875_m1 
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Pomc* pro-opiomelanocortin-alpha MGI:97742 Mm00435874_m1 
Pspn persephin MGI:1201684 Mm03024006_m1 
Ptgs2 
prostaglandin-endoperoxide 
synthase 2 MGI:97798 Mm01307329_m1 
Sst* somatostatin MGI:98326 Mm00436671_m1 
Tac1 tachykinin 1 MGI:98474 Mm01166996_m1 
Tacr1 tachykinin receptor 1 MGI:98475 Mm00436892_m1 
Tnf tumor necrosis factor MGI:104798 Mm00443258_m1 
Trpa1 
transient receptor potential cation 
channel, subfamily A, member 1 MGI:3522699 Mm00625268_m1 
Trpm8* 
transient receptor potential cation 
channel, subfamily M, member 8 MGI:2181435 Mm00454566_m1 
Trpv1 
transient receptor potential cation 
channel, subfamily V, member 1 MGI:1341787 Mm01246282_m1 
Trpv3* 
transient receptor potential cation 
channel, subfamily V, member 3 MGI:2181407 Mm00454996_m1 
Trpv4 
transient receptor potential cation 
channel, subfamily V, member 4 MGI:1926945 Mm00499025_m1 
Ucn* urocortin MGI:1276123 Mm00445261_m1 
Vegfa 
vascular endothelial growth factor 
A MGI:103178 Mm01281449_m1 
Vip* vasoactive intestinal polypeptide MGI:98933 Mm00660234_m1 
*=Not Detected in the mouse knee (8 weeks post surgery) 
 
 
1. Dawes JM AD, Bennett DLH, Bevan S, McMahon SB. Inflammatory Mediators 
and Modulators of Pain. In: McMahon SB KM, Tracey I, Turk DC, editor. Melzack & 
Wall's Textbook of Pain 6th edition. 6th Edition ed. Philadelphia USA: Elsevier; 2013. 
p. 48-67. 
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Supplementary table 2. List of SYBR-Green® primers used for qPCR in 
porcine tissues. 
 
Target Accession 
number 
Orientation Primer Sequence 5’-3’ 
18s NM213940.1 sense TGTGGTGTTGAGGAAAGCAG 
antisense GGAATCTTGTATTGGCGAGG 
Ngf XM003481483.2 
 
sense CACTGGAACTCGTATTGTACCACAA 
antisense GCCTGCTTGCCGTCCAT 
Bdkrb1 NM001113064.
1 
sense TCTGCCGCGTGGTCAAC 
antisense ACCACCAGGAAGATGCTGATG 
Bdkrb2 NM214146.1 sense CGCCTCTTTTCCGCTTTCT 
antisense CGGGCTCCGGGACTTG 
Tac1 XM003357447.3 sense GATGCTGGACATGGCCAGAT 
antisense TCATAATTCTGCATTGCACTCCTT 
